STRATEC adopts dividend proposal for 2013 financial year

Birkenfeld, April 25, 2014

The Board of Management and Supervisory Board of STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) will be proposing the distribution of a dividend of EUR 0.60 per share with dividend rights for the 2013 financial year for approval by the Annual General Meeting on June 18, 2014 (distribution in 2013 for the 2012 financial year: EUR 0.56). At its meeting today, the Supervisory Board endorsed the corresponding recommendation submitted by the Board of Management. Subject to approval by the Annual General Meeting, shareholders can expect to benefit from the tenth dividend increase in succession since the first dividend payment in 2004.

About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com